Comparison of safety and efficaccy of levocetrizine and olopatadine in patients suffering from hives for more than 6 weeks

A single-blind randomized controlled clinical study comparing the efficacy, tolerability and safety of levocetrizine and olopatadine in chronic urticaria - ESLO

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/08/001965

Enrollment

120

Registered

2011-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Urticaria

Interventions

Intervention1: Levocetrizine, Olopatadine: Levocetrizine oral Tablets containing 5 mg once daily Olopatadine oral tablets 5 mg twice daily Intervention2: Olopatdaine oral tablets: Olopatadine (5mg) or

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age above 18 years 2. Patients of either sex 3. Patients suffering from urticaria for more than 6 weeks

Exclusion criteria

Exclusion criteria: 1 Pregnant or nursing women 2 End stage renal disease 3 Patients having immunosuppression due to drug or disease 4 History of alcohol or substance abuse 5 Subjects working in night-shifts or are likely to change the usual sleep/wake cycle. 6 Patients driving automobiles. 7 Participation in any other clinical trial within past 3 months 8 Patients unwilling to provide written informed consent or unlikely to comply with the trial protocol 9 Any other condition, which in the opinion of the investigators, is not conducive to inclusion of the subject in the trial

Design outcomes

Primary

Measure	Time frame
Urticaria Severity Score(UAS) Total Symptom Severity Score (TSS), Patients and Physicians global assessment of disease activity improvement (5 point Likert scale)Timepoint: 4,9 weeks after randomisation	—

Secondary

Measure	Time frame
LFT Routine haemogram Serum Urea, Creatinine Reported adverse effectsTimepoint: Baseline and 4 weeks after randomisation Adverse effects recorded at 1, 2, 3, 4, 5, 9 weeks of randomisation	—

Countries

India

Contacts

Public ContactAmrita Sil

Department of Clinical and Experimental Pharmacology

tripathi.santanu@gmail.com09230566771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 24, 2026